IGC PharmaIGC
Market Cap: $22.5M
About: IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Employees: 61
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
18% more capital invested
Capital invested by funds: $944K [Q1] → $1.11M (+$166K) [Q2]
0.26% more ownership
Funds ownership: 3.57% [Q1] → 3.83% (+0.26%) [Q2]
0% more funds holding
Funds holding: 24 [Q1] → 24 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Ascendiant Capital Edward Woo 42% 1-year accuracy 16 / 38 met price target | 1,014%upside $3.75 | Buy Maintained | 3 Sept 2024 |
Ascendiant Capital Edward Woo 42% 1-year accuracy 16 / 38 met price target | 940%upside $3.50 | Buy Maintained | 29 Jul 2024 |
Alliance Global Partners James Molloy 0% 1-year accuracy 0 / 7 met price target | 940%upside $3.50 | Buy Initiated | 17 Jul 2024 |
Ascendiant Capital Edward Woo 42% 1-year accuracy 16 / 38 met price target | 866%upside $3.25 | Buy Reiterated | 21 Jun 2024 |
Financial journalist opinion
Based on 3 articles about IGC published over the past 30 days